Clinical Trial
Danielle Antin-Ozerkis
1305-0014: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) (FIBRONEER-IPF)
- Ages18 years and older
- GenderBoth